Company: RPTX
Filing Date: 2025-05-01
Form Type: 8-K
Source: 0001193125-25-108730
Chunk: 0

Company: Repare Therapeutics Inc.
Filing Date: 2025-05-01
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01      Regulation FD Disclosure.  

On May 1, 2025, Repare Therapeutics Inc. (the “ Company”) issued a press release announcing an agreement to out-licenseits discovery platforms, including certain platform and program intellectual property, to DCx Biotherapeutics Corporation, a British Columbia-based biotechnology company. A copy of the press release is furnished as Exhibit 99.1 to this Current Report and incorporated herein by reference.

The information in this Current Report on Form8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.